• We argued that the company is a ground-floor opportunity on the regenerative medicine revolution, which is just in the early innings.
• The company is winning dozens of new customers a quarter, increasing the pool of possible regulatory approvals and the accompanying prospect of a step up in revenues.
• Already profitable and cash generating, the shares aren’t all that expensive.

Source: It’s Still Not Too Late To Get On Board Of The BioLife Solutions Train – BioLife Solutions, Inc. (NASDAQ:BLFS) | Seeking Alpha